Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1981 Jun;73(2):373–377. doi: 10.1111/j.1476-5381.1981.tb10431.x

Antifibrillatory efficacy of encainide, loracainide and ORG 6001 compared with lignocaine in isolated hearts of rabbits and guinea-pigs.

A A Almotrefi, J B Baker
PMCID: PMC2071657  PMID: 6786403

Abstract

1 In Langendorff-perfused rabbit hearts, electrical stimulation threshold and ventricular fibrillation threshold (VFT) were measured by applying rectangular impulses of 3 ms duration and increasing current at frequencies of 4 and 20 Hz respectively. 2 Perfusion with lignocaine or one of three new antiarrhythmic drugs, encainide, lorcainide and ORG 6001, produced significant, dose-dependent increases in both thresholds. 3 On a dosage basis, encainide was seven times, lorcainide fourteen times and ORG 6001 twice as potent as lignocaine in raising VFT. 4 In Langendorff-perfused guinea-pig hearts, only lorcainide provided complete protection against ouabain-induced ventricular fibrillation, while 6 of 6, 3 of 6 and 2 of 6 hearts fibrillated in the presence of encainide, lignocaine and ORG 6001 respectively, but with infusion durations significantly higher than control. 5 These results indicate the potential antifibrillatory activity of these new antiarrhythmic agents.

Full text

PDF
373

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Almotrefi A. A., Baker J. B. Investigation of the antifibrillatory activity of some anticonvulsant gamma-aminobutyric acid-transaminase inhibitors in the rabbit isolated heart: comparison with phenytoin and mexiletine. Br J Pharmacol. 1980;71(2):635–639. doi: 10.1111/j.1476-5381.1980.tb10984.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Almotrefi A. A., Baker J. B. The antifibrillatory potency of aprindine, mexiletine, tocainide and lignocaine compared on Langendorff-perfused hearts of rabbits and guinea-pigs. J Pharm Pharmacol. 1980 Nov;32(11):746–750. doi: 10.1111/j.2042-7158.1980.tb13059.x. [DOI] [PubMed] [Google Scholar]
  3. Baum T., Eckfeld D. K., Shropshire A. T., Rowles G., Varner L. L. Observations on models used for the evaluation of antiarrhythmic drugs. Arch Int Pharmacodyn Ther. 1971 Sep;193(1):149–170. [PubMed] [Google Scholar]
  4. Byrne J. E., Gomoll A. W., McKinney G. R. Antiarrhythmic properties of MJ 9067 in acute animal models. J Pharmacol Exp Ther. 1977 Jan;200(1):147–154. [PubMed] [Google Scholar]
  5. Carmeliet E., Janssen P. A., Marsboom R., Van Nueten J. M., Xhonneux R. Antiarrhythmic, electrophysiologic and hemodynamic effects of lorcainide. Arch Int Pharmacodyn Ther. 1978 Jan;231(1):104–130. [PubMed] [Google Scholar]
  6. Gibson J. K., Somani P., Bassett A. L. Electrophysiologic effects of encainide (MJ 9067) on canine Purkinje fibres. Eur J Pharmacol. 1978 Nov 15;52(2):161–169. doi: 10.1016/0014-2999(78)90202-9. [DOI] [PubMed] [Google Scholar]
  7. Kesteloot H., Stroobandt R. Clinical experience with lorcainide (R 15 889), a new anti-arrhythmic drug. Arch Int Pharmacodyn Ther. 1977 Dec;230(2):225–234. [PubMed] [Google Scholar]
  8. Klotz U., Müller-Seydlitz P., Heimburg P. Disposition and antiarrhythmic effect of lorcainide. Int J Clin Pharmacol Biopharm. 1979 Apr;17(4):152–158. [PubMed] [Google Scholar]
  9. MCEWEN L. M. The effect on the isolated rabbit heart of vagal stimulation and its modification by cocaine, hexamethonium and ouabain. J Physiol. 1956 Mar 28;131(3):678–689. doi: 10.1113/jphysiol.1956.sp005493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Marshall R. J., Parratt J. R. Antiarrhythmic, haemodynamic and metabolic effects of 3alpha-amino-5alpha-androstan-2beta-ol-17-one hydrochloride in greyhounds following acute coronary artery ligation. Br J Pharmacol. 1975 Nov;55(3):359–368. doi: 10.1111/j.1476-5381.1975.tb06939.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Moore E. N., Spear J. F. Ventricular fibrillation threshold; its physiological and pharmacological importance. Arch Intern Med. 1975 Mar;135(3):446–453. doi: 10.1001/archinte.135.3.446. [DOI] [PubMed] [Google Scholar]
  12. Salako L. A., Williams V., Wittig J. H. Investigations to characterize a new anti-arrhythmic drug, ORG 6001 including a simple test for calcium antagonism. Br J Pharmacol. 1976 Jun;57(2):251–262. doi: 10.1111/j.1476-5381.1976.tb07475.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Sami M., Mason J. W., Peters F., Harrison D. C. Clinical electrophysiologic effects of encainide, a newly developed antiarrhythmic agent. Am J Cardiol. 1979 Sep;44(3):526–532. doi: 10.1016/0002-9149(79)90407-7. [DOI] [PubMed] [Google Scholar]
  14. Vargaftig B. B., Sugrue M. F., Buckett W. R., van Riezen H. ORG 6001 (3alpha-amino-5alpha-androstan-2beta-ol-17-one hydrochloride), a steroidal anti-arrhythmic agent. J Pharm Pharmacol. 1975 Sep;27(9):697–699. doi: 10.1111/j.2042-7158.1975.tb09535.x. [DOI] [PubMed] [Google Scholar]
  15. Verdouw P. D., Schamhardt H. C., Remme W. J., De Jong J. W. Antiarrhythmic, metabolic and hemodynamic effects of Org 6001 (3alpha-amino-5alpha-androstan-2beta-ol-17-one-hydrochloride) after coronary flow reduction in pigs. J Pharmacol Exp Ther. 1978 Mar;204(3):634–644. [PubMed] [Google Scholar]
  16. WILLIAMS E. M., SEKIYA A. Prevention of arrhythmias due to cardiac glycosides by block of sympathetic beta receptors. Lancet. 1963 Feb 23;1(7278):420–421. doi: 10.1016/s0140-6736(63)92306-7. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES